Literature DB >> 12951585

Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Mark E Dudley1, Steven A Rosenberg.   

Abstract

Adoptive immunotherapy--the isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration--is a promising approach to inducing antitumour immune responses. The molecular identification of tumour antigens and the ability to monitor the persistence and transport of transferred cells has provided new insights into the mechanisms of tumour immunotherapy. Recent studies have shown the effectiveness of cell-transfer therapies for the treatment of patients with selected metastatic cancers. These studies provide a blueprint for the wider application of adoptive-cell-transfer therapy, and emphasize the requirement for in vivo persistence of the cells for therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951585      PMCID: PMC2305722          DOI: 10.1038/nrc1167

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  97 in total

Review 1.  CD8+ T cell effector mechanisms in resistance to infection.

Authors:  J T Harty; A R Tvinnereim; D W White
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

Review 3.  Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.

Authors:  J A Kim; H S Bresler; E W Martin; W Aldrich; M Heffelfinger; P L Triozzi
Journal:  Cancer       Date:  1999-07-01       Impact factor: 6.860

7.  Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

Authors:  J R Yannelli; C Hyatt; S McConnell; K Hines; L Jacknin; L Parker; M Sanders; S A Rosenberg
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

8.  Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.

Authors:  J R Berenson; A B Einstein; A Fefer
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

9.  Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.

Authors:  W C To; B G Wood; J C Krauss; M Strome; R M Esclamado; P Lavertu; D Dasko; J A Kim; G E Plautz; B E Leff; V Smith; K Sandstrom-Wakeling; S Shu
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2000-10

10.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  206 in total

1.  Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81.

Authors:  Yael Sagi; Angela Landrigan; Ronald Levy; Shoshana Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

Review 2.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

3.  Bone marrow vaccination: a novel approach to enhance antigen specific antitumor immunity.

Authors:  Stephanie Fresnay; Xiaoyu Zhang; Scott E Strome; Duane A Sewell
Journal:  Vaccine       Date:  2011-09-25       Impact factor: 3.641

4.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Authors:  E Liu; Y Tong; G Dotti; H Shaim; B Savoldo; M Mukherjee; J Orange; X Wan; X Lu; A Reynolds; M Gagea; P Banerjee; R Cai; M H Bdaiwi; R Basar; M Muftuoglu; L Li; D Marin; W Wierda; M Keating; R Champlin; E Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-07-20       Impact factor: 11.528

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression.

Authors:  Akio Ohta; J Kjaergaard; S Sharma; M Mohsin; N Goel; M Madasu; E Fradkov; Akiko Ohta; M Sitkovsky
Journal:  Br J Pharmacol       Date:  2008-12-09       Impact factor: 8.739

7.  Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Authors:  Xiuli Wang; Araceli Naranjo; Christine E Brown; Cherrilyn Bautista; Chinglam W Wong; Wen-Chung Chang; Brenda Aguilar; Julie R Ostberg; Stanley R Riddell; Stephen J Forman; Michael C Jensen
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

8.  Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.

Authors:  David M Barrett; Nathan Singh; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Cytotherapy       Date:  2014-01-16       Impact factor: 5.414

9.  B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.

Authors:  Ming-Ru Wu; Tong Zhang; Albert T Gacerez; Tiffany A Coupet; Leslie R DeMars; Charles L Sentman
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.